Physician profile
Gary M Levine
NPI 1902977796
$7,285.71
in general payments reported to CMS, 2019-2025
30 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,712 · 2020: $122 · 2021: $159 · 2022: $379 · 2023: $241 · 2024: $420 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Samsung Hme America, INC. | $5,250.00 | 2019 | |
| Abbvie INC. | $327.15 | 2019-2023 | |
| Hologic Sales and Service, LLC | $262.06 | 2023-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Roche Diagnostics Corporation | $186.68 | 2019 | |
| Amgen INC. | $144.64 | 2020-2025 | Evenity, Prolia |
| Exeltis, USA INC. | $132.65 | 2019-2025 | Slynd |
| Merck Sharp & Dohme LLC | $108.14 | 2019-2025 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $89.85 | 2019-2024 | Paragard T 380a |
| Organon LLC | $85.01 | 2021-2024 | |
| Aspira Women'S Health INC | $82.25 | 2022 | |
| Millicent US INC | $77.62 | 2020-2025 | Intrarosa |
| Astellas Pharma US INC | $76.70 | 2022-2025 | Veozah |
| Celularity INC. | $74.00 | 2019-2022 | |
| Allergan, INC. | $57.70 | 2019 | |
| Therapeuticsmd, INC. | $37.72 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicem INC. | $34.24 | 2022 | |
| Lupin INC. | $32.92 | 2020 | |
| Mimedx Group, INC. | $28.84 | 2024 | |
| Channel Medsystems, INC. | $26.19 | 2022-2025 | |
| Smith+Nephew, INC. | $25.69 | 2025 | Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Becton, Dickinson and Company | $25.25 | 2019 | |
| Evofem Biosciences, INC. | $18.72 | 2024 | |
| Duchesnay USA Incorporated | $17.45 | 2019 | |
| Teleflex LLC | $17.25 | 2020 | |
| Pfizer INC. | $15.82 | 2023 | |
| Gynesonics, INC. | $13.97 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Avion Pharmaceuticals | $13.36 | 2022 | |
| Mayne Pharma Commercial LLC | $12.48 | 2025 | |
| Minerva Surgical, INC | $11.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.